Proteogenomic Monitoring and Assessment of Liver Transplant Recipients

Part of paid clinical trials in Chicago, Illinois.

Sponsor
Northwestern University
Study ID
NCT01644903
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Study Details

This study is being done to test blood, urine and tissue samples to see if this can help decide if CKD (Chronic Kidney Disease), AR (Acute Rejection) and HCV (Hepatitis C Virus) can be identified in its early stages. CKD damage to the kidneys, AR and HCV all lower the body's ability to function properly. Early detection of these conditions could assist with successful treatment and possibly lead to less repeat organ transplants.

Key Dates

Start date
Apr 30, 2010
Status verified
May 2026
Primary completion
Dec 31, 2030
Completion
Dec 31, 2031

Study Design

Enrollment
1,000 participants (estimated)

Primary Outcome Measure

Proteogenomic Biomarkers for CKD, AR and HCV [ Time Frame: At time of liver biopsy ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Northwestern Memorial HospitalChicagoIllinois60611
Misael Villegas, BA
[email protected]
Jairo Chavez, BA
[email protected]

Find similar trials in Chicago, IL

By condition
Chronic kidney disease
By specialty
NephrologyKidney disease
By research site
Northwestern Memorial Hospital· Chicago, IL

Related Studies